Globus Medical, Inc.

Valuation Analysis

About the Company

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies;

Globus Medical, Inc. Stock at a Glance

Globus Medical, Inc. (GMED) is currently trading at $80.39 with a market capitalization of $10.9B. The trailing P/E ratio stands at 18.78x, with a forward P/E of 15.61x. The 52-week range spans from $51.79 to $101.40; the current price is 20.7% below the yearly high. Year-over-year revenue growth stands at +27.0%. The net profit margin stands at 18.92%.

💰 Dividend

Globus Medical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

11 analysts rate Globus Medical, Inc. (GMED) on consensus: Buy. The average price target is $110.00, implying +36.83% from the current price. Analyst price targets range from $87.00 to $122.00.

Globus Medical, Inc.: The Investment Case in Detail

Globus Medical, Inc. (GMED) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 27% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 68.49%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 18.92%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valuation in Context

The PEG ratio at 1.49 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 15.61x is meaningfully below the trailing 18.78x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 36.83% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Globus Medical, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.